Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolum...

Source: Journal of Hematology and Oncology - April 23, 2018 Category: Hematology Authors: Yucai Wang, Grzegorz S. Nowakowski, Michael L. Wang and Stephen M. Ansell Tags: Review Source Type: research